{"nctId":"NCT01104584","briefTitle":"Efficacy and Safety of Gadobutrol 1.0 Molar (Gadovist) for Breast Magnetic Resonance Imaging (MRI)","startDateStruct":{"date":"2010-05"},"conditions":["Breast Cancer"],"count":460,"armGroups":[{"label":"Gadobutrol (Gadavist, BAY86-4875)","type":"EXPERIMENTAL","interventionNames":["Drug: Gadobutrol (Gadavist, Gadovist, BAY86-4875)"]}],"interventions":[{"name":"Gadobutrol (Gadavist, Gadovist, BAY86-4875)","otherNames":[]}],"eligibilityModule":{"eligibilityCriteria":"Inclusion Criteria:\n\n* Recent histologically proven diagnosis of breast cancer after having obtained X-Ray Mammography (XRM) of both breasts (according to American College of Radiology \\[ACR\\] and performed no longer than 6 weeks prior to enrollment into the study) and has been referred for a contrast-enhanced Magnetic Resonance Mammography (MRM) prior to surgery of the breast.\n* if female, a digital XRM is required if any of the following criteria is met:\n\n  * a. patient is younger than 50 years;\n  * b. patient has heterogeneously or extremely dense breasts;\n  * c. is not post-menopausal (post-menopause defined as at least 12 months prior to inclusion without menstruation).\n* if female of childbearing potential, MRM should be performed on the 7-14th day of the menstrual cycle.\n* has an estimated glomerular filtration rate (eGFR) value \\>/= 60 mL/min/1.73m\\^2 derived from a serum creatinine result within 2 weeks prior to study enrollment.\n\nExclusion Criteria:\n\n* is a female patient who is pregnant or lactating\n* has any contraindication to the MRM examination (e.g. metal implants, phobia) or the use of gadolinium-containing contrast agents.\n* has received any contrast agent within 24 hours prior to the study MRM, or is scheduled to receive any contrast agent within 24 hours after the study MRM.\n* has severe cardiovascular disease (e.g., known long QT syndrome, acute myocardial infarction \\[\\< 14 days\\], unstable angina, congestive heart failure New York Heart Association class IV) or acute stroke (\\< 48 hours)).\n* has acute renal insufficiency of any severity due to hepato-renal syndrome or in the peri-operative liver transplantation period or who has acute or chronic moderate or severe renal insufficiency (glomerular filtration rate \\< 60 mL/min/1.73m\\^2).\n* has received chemotherapy or hormonal therapy for breast cancer within 6 months.\n* has received hormone replacement therapy within 4 weeks prior to study drug administration.\n* is scheduled or likely to require a surgery and/or biopsy in the time period up to 24 hours following study drug application\n* has prior excisional biopsy or breast surgery less than 6 months before enrollment and between XRM and study MRM","healthyVolunteers":false,"sex":"ALL","minimumAge":"18 Years","stdAges":["ADULT","OLDER_ADULT"]},"locations":{"multicenter":true},"periods":[],"outcomeMeasures":[{"type":"PRIMARY","title":"Difference of Sensitivity for Detection of Full Extent of Malignant Breast Disease Using CMRM vs UMRM Per Reader","description":"For a single participant the sensitivity was defined as the proportion of malignant breast regions that were recognized by the clinical investigators and the 3 blinded readers using the respective imaging modality as malignant. Subsequently the sensitivity percentage was calculated based on the mean of the sensitivities across all participants. The difference was calculated as CMRM value minus UMRM value. For ease of expression, the following abbreviations will be used: Magnetic Resonance Mammography (MRM), Unenhanced MRM (UMRM), combined unenhanced and contrast (gadobutrol)-enhanced MRM (CMRM), X-ray mammography (XRM).","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"15.2","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"31.9","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"30.4","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"15.9","spread":null}]}]}]},{"type":"PRIMARY","title":"Sensitivity for Detection of Full Extent of Malignant Breast Disease Using CMRM vs UMRM Per Reader","description":"For a single participant the sensitivity was defined as the proportion of malignant breast regions that were recognized by the clinical investigators and the 3 blinded readers using the respective imaging modality as malignant. Subsequently the sensitivity percentage was calculated based on the mean of the sensitivities across all participants.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"88.6","spread":null},{"groupId":"OG001","value":"73.3","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"89.0","spread":null},{"groupId":"OG001","value":"57.0","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"85.5","spread":null},{"groupId":"OG001","value":"55.1","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"95.5","spread":null},{"groupId":"OG001","value":"79.5","spread":null}]}]}]},{"type":"PRIMARY","title":"Breast Level Specificity of CMRM for Non-malignant Breasts by Reader","description":"A non-malignant breast was defined as false positive (FP), when the reader assessed at least one breast region as malignant. When all breast regions were assessed as non-malignant, the breast was defined as true negative (TN). Breast level specificity was first defined in participant as number of TN-breasts in participant divided by number of non-malignant breasts in participant. Subsequently the specificity percentage was calculated based on the mean of the specificities across all participants who contributed with at least one non-malignant breast.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"91.8","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"83.9","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"82.8","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"95.4","spread":null}]}]}]},{"type":"SECONDARY","title":"Breast Level Specificity of CMRM Based on Malignant Breasts","description":"A malignant breast was defined as FP, when the reader using the respective imaging modality assessed more breast regions as malignant as were present according to SoT. Otherwise the breast was assessed as TN. Specificity was then defined as TN/(TN+FP).","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"54.9","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"47.2","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"55.5","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"93.8","spread":null}]}]}]},{"type":"SECONDARY","title":"Percentage Difference of Participants Whose Index Cancers Were Detected Using CMRM vs UMRM, CMRM vs XRM, and CMRM vs CMRM+XRM","description":"Index cancer was defined as the cancer confirmed by histology prior to inclusion which made the participants eligible for the study. The difference in percentage of participants was calculated as CMRM value minus UMRM value, CMRM value minus XRM value, CMRM value minus CMRM+XRM value respectively.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"15.5","spread":null},{"groupId":"OG001","value":"19.8","spread":null},{"groupId":"OG002","value":"-1.0","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"30.2","spread":null},{"groupId":"OG001","value":"13.9","spread":null},{"groupId":"OG002","value":"-1.3","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"30.9","spread":null},{"groupId":"OG001","value":"12.9","spread":null},{"groupId":"OG002","value":"-2.6","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"14.2","spread":null},{"groupId":"OG001","value":"2.3","spread":null},{"groupId":"OG002","value":"-0.5","spread":null}]}]}]},{"type":"SECONDARY","title":"Percentage Difference of Participants Whose Additional Index Cancers Were Detected Using CMRM vs UMRM, CMRM vs XRM, and CMRM vs CMRM+XRM","description":"Additional cancer was defined as cancer which was present according to SoT, but which was not defined as index cancer, i.e. was not known when the participant was enrolled into the study. The difference in percentage of participants was calculated as CMRM value minus UMRM value, CMRM value minus XRM value, CMRM value minus CMRM+XRM value respectively.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"23.8","spread":null},{"groupId":"OG001","value":"42.9","spread":null},{"groupId":"OG002","value":"0.0","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"44.0","spread":null},{"groupId":"OG001","value":"48.8","spread":null},{"groupId":"OG002","value":"0.0","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"34.5","spread":null},{"groupId":"OG001","value":"26.2","spread":null},{"groupId":"OG002","value":"-2.4","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"35.7","spread":null},{"groupId":"OG001","value":"40.5","spread":null},{"groupId":"OG002","value":"-1.2","spread":null}]}]}]},{"type":"SECONDARY","title":"Difference of Confidence in Diagnosis for Breast Region Diagnosis Using CMRM vs UMRM, CMRM+XRM vs UMRM+XRM and CMRM+XRM vs XRM by Reader, Participant Level","description":"The investigator and the blinded readers each recorded his/her confidence in diagnosis for each breast region based on a 4-point scale (1 = not confident, 2 = somewhat confident, 3 = confident, and 4 = very confident). For each participant, the mean of the confidence responses for the diagnosed breast regions was calculated, and rounded to the nearest 0.5. The difference was calculated as CMRM value minus UMRM value, CMRM+XRM value minus UMRM+XRM value, CMRM+XRM value minus XRM value respectively.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"0.97","spread":null},{"groupId":"OG001","value":"1.25","spread":null},{"groupId":"OG002","value":"-0.23","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"0.95","spread":null},{"groupId":"OG001","value":"0.74","spread":null},{"groupId":"OG002","value":"0.04","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"1.73","spread":null},{"groupId":"OG001","value":"1.64","spread":null},{"groupId":"OG002","value":"0.67","spread":null}]}]}]},{"type":"OTHER_PRE_SPECIFIED","title":"Sensitivity for Detection of Full Extent of Malignant Breast Disease Using XRM, CMRM+XRM and UMRM+XRM Per Reader","description":"For a single participant the sensitivity was defined as the proportion of malignant breast regions that were recognized by the reader using the respective imaging modality as malignant. Subsequently the sensitivity percentage was calculated based on the mean of the sensitivities across all participants.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"69.6","spread":null},{"groupId":"OG001","value":"89.6","spread":null},{"groupId":"OG002","value":"82.5","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"72.9","spread":null},{"groupId":"OG001","value":"90.3","spread":null},{"groupId":"OG002","value":"80.9","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"73.2","spread":null},{"groupId":"OG001","value":"88.0","spread":null},{"groupId":"OG002","value":"80.1","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"89.1","spread":null},{"groupId":"OG001","value":"96.0","spread":null},{"groupId":"OG002","value":"92.1","spread":null}]}]}]},{"type":"OTHER_PRE_SPECIFIED","title":"Breast Level Specificity of in Non-malignant Breasts Using UMRM, XRM, CMRM+XRM and UMRM+XRM by Reader","description":"A non-malignant breast was defined as false positive (FP), when the reader assessed at least one breast region as malignant. When all breast regions were assessed as non-malignant, the breast was defined as true negative (TN). Breast level specificity was first defined in participant as number of TN-breasts in participant divided by number of non-malignant breasts in participant. Subsequently the specificity percentage was calculated based on the mean of the specificities across all participants who contributed with at least one non-malignant breast.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"94.4","spread":null},{"groupId":"OG001","value":"92.6","spread":null},{"groupId":"OG002","value":"92.2","spread":null},{"groupId":"OG003","value":"94.3","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"96.6","spread":null},{"groupId":"OG001","value":"90.3","spread":null},{"groupId":"OG002","value":"83.1","spread":null},{"groupId":"OG003","value":"91.0","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"95.9","spread":null},{"groupId":"OG001","value":"86.1","spread":null},{"groupId":"OG002","value":"83.0","spread":null},{"groupId":"OG003","value":"85.1","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"98.1","spread":null},{"groupId":"OG001","value":"97.8","spread":null},{"groupId":"OG002","value":"95.1","spread":null},{"groupId":"OG003","value":"97.5","spread":null}]}]}]},{"type":"OTHER_PRE_SPECIFIED","title":"Breast Level Specificity in Malignant Breasts Using UMRM, XRM, CMRM+XRM and UMRM+XRM by Reader","description":"A malignant breast was defined as FP, when the reader using the respective imaging modality assessed more breast regions as malignant as were present according to SoT. Otherwise the breast was assessed as TN. Specificity was then defined as TN/(TN+FP).","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"71.9","spread":null},{"groupId":"OG001","value":"86.8","spread":null},{"groupId":"OG002","value":"52.7","spread":null},{"groupId":"OG003","value":"69.1","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"76.2","spread":null},{"groupId":"OG001","value":"75.8","spread":null},{"groupId":"OG002","value":"46.5","spread":null},{"groupId":"OG003","value":"65.4","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"77.6","spread":null},{"groupId":"OG001","value":"69.4","spread":null},{"groupId":"OG002","value":"54.5","spread":null},{"groupId":"OG003","value":"66.9","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"96.2","spread":null},{"groupId":"OG001","value":"97.7","spread":null},{"groupId":"OG002","value":"93.8","spread":null},{"groupId":"OG003","value":"96.0","spread":null}]}]}]},{"type":"OTHER_PRE_SPECIFIED","title":"Breast Level Specificity for All Breasts by Imaging Modality and by Reader","description":"A non-malignant breast was defined as FP when the reader assessed at least one breast region as malignant. A malignant breast was defined as FP, when the reader using the respective imaging modality assessed more breast regions as malignant as were present according to SoT. Otherwise the breast was assessed as TN. Specificity was then defined as (N-FP)/N, where N was total number of breasts.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"83.0","spread":null},{"groupId":"OG001","value":"73.0","spread":null},{"groupId":"OG002","value":"89.7","spread":null},{"groupId":"OG003","value":"81.3","spread":null},{"groupId":"OG004","value":"72.0","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"86.1","spread":null},{"groupId":"OG001","value":"64.9","spread":null},{"groupId":"OG002","value":"83.0","spread":null},{"groupId":"OG003","value":"77.8","spread":null},{"groupId":"OG004","value":"64.3","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"86.5","spread":null},{"groupId":"OG001","value":"68.6","spread":null},{"groupId":"OG002","value":"77.6","spread":null},{"groupId":"OG003","value":"75.9","spread":null},{"groupId":"OG004","value":"68.1","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"96.6","spread":null},{"groupId":"OG001","value":"94.1","spread":null},{"groupId":"OG002","value":"97.1","spread":null},{"groupId":"OG003","value":"96.2","spread":null},{"groupId":"OG004","value":"94.0","spread":null}]}]}]},{"type":"OTHER_PRE_SPECIFIED","title":"Sensitivity Difference in the Determination of Malignant Breast Disease Using CMRM vs UMRM, CMRM+XRM vs UMRM+XRM, and CMRM+XRM vs XRM Verified by SoT, Breast Region Level","description":"For a single participant the sensitivity was defined as the proportion of malignant breast regions that were recognized by the reader using the respective imaging modality as malignant. Subsequently the point estimates were calculated based on the mean of the sensitivities across all participants. Regions with malignant disease verified by SoT comprise unifocal and multifocal regions. Difference in sensitivity is calculated as CMRM value minus UMRM value, CMRM+XRM value minus UMRM+XRM value, CMRM+XRM value minus XRM value respectively.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"17.5","spread":null},{"groupId":"OG001","value":"9.5","spread":null},{"groupId":"OG002","value":"24.3","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"34.9","spread":null},{"groupId":"OG001","value":"12.5","spread":null},{"groupId":"OG002","value":"21.3","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"32.1","spread":null},{"groupId":"OG001","value":"10.0","spread":null},{"groupId":"OG002","value":"16.5","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"19.0","spread":null},{"groupId":"OG001","value":"6.7","spread":null},{"groupId":"OG002","value":"10.5","spread":null}]}]}]},{"type":"OTHER_PRE_SPECIFIED","title":"Sensitivity Difference in the Determination of Unifocal Malignant Breast Disease Using CMRM vs UMRM, CMRM+XRM vs UMRM+XRM, and CMRM+XRM vs XRM Verified by SoT, Breast Region Level","description":"For a single participant the sensitivity was defined as the proportion of malignant breast regions that were recognized by the reader using the respective imaging modality as malignant. Subsequently the point estimates were calculated based on the mean of the sensitivities across all participants. The difference in sensitivity is calculated as CMRM value minus UMRM value, CMRM+XRM value minus UMRM+XRM value, CMRM+XRM value minus XRM value respectively.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"-5.8","spread":null},{"groupId":"OG001","value":"-12.6","spread":null},{"groupId":"OG002","value":"-10.2","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"4.6","spread":null},{"groupId":"OG001","value":"-12.3","spread":null},{"groupId":"OG002","value":"-12.0","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"19.5","spread":null},{"groupId":"OG001","value":"-1.9","spread":null},{"groupId":"OG002","value":"6.9","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"12.0","spread":null},{"groupId":"OG001","value":"0.2","spread":null},{"groupId":"OG002","value":"2.3","spread":null}]}]}]},{"type":"OTHER_PRE_SPECIFIED","title":"Sensitivity Difference in the Determination of Multifocal Malignant Breast Disease Using CMRM vs UMRM, CMRM+XRM vs UMRM+XRM, and CMRM+XRM vs XRM Verified by SoT, Breast Region Level","description":"For a single participant the sensitivity was defined as the proportion of malignant breast regions that were recognized by the reader using the respective imaging modality as malignant. Subsequently the point estimates were calculated based on the mean of the sensitivities across all participants. The difference in sensitivity is calculated as CMRM value minus UMRM value, CMRM+XRM value minus UMRM+XRM value, CMRM+XRM value minus XRM value respectively.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"46.7","spread":null},{"groupId":"OG001","value":"40.0","spread":null},{"groupId":"OG002","value":"65.0","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"51.7","spread":null},{"groupId":"OG001","value":"35.0","spread":null},{"groupId":"OG002","value":"46.7","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"31.7","spread":null},{"groupId":"OG001","value":"21.7","spread":null},{"groupId":"OG002","value":"11.7","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"25.4","spread":null},{"groupId":"OG001","value":"21.7","spread":null},{"groupId":"OG002","value":"36.7","spread":null}]}]}]},{"type":"OTHER_PRE_SPECIFIED","title":"Specificity Difference in the Determination of Malignant Breast Disease Using CMRM vs UMRM, CMRM+XRM vs UMRM+XRM, and CMRM+XRM vs XRM Verified by SoT, Breast Region Level","description":"A malignant breast was defined as FP, when the reader using the respective imaging modality assessed more breast regions as malignant as were present according to SoT. Otherwise the breast was assessed as TN. Specificity was then defined as TN/(TN+FP). The difference was calculated as CMRM value minus UMRM value, CMRM+XRM value minus UMRM+XRM value, CMRM+XRM value minus XRM value respectively.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"-4.1","spread":null},{"groupId":"OG001","value":"-3.9","spread":null},{"groupId":"OG002","value":"-6.7","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"-8.4","spread":null},{"groupId":"OG001","value":"-5.7","spread":null},{"groupId":"OG002","value":"-7.5","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"-6.1","spread":null},{"groupId":"OG001","value":"-2.0","spread":null},{"groupId":"OG002","value":"-3.2","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"-1.0","spread":null},{"groupId":"OG001","value":"-0.9","spread":null},{"groupId":"OG002","value":"-1.3","spread":null}]}]}]},{"type":"OTHER_PRE_SPECIFIED","title":"Specificity Difference in the Determination of Unifocal Malignant Breast Disease Using CMRM vs UMRM, CMRM+XRM vs UMRM+XRM, and CMRM+XRM vs XRM Verified by SoT, Breast Region Level","description":"A malignant breast was defined as FP, when the reader using the respective imaging modality assessed more breast regions as malignant as were present according to SoT. Otherwise the breast was assessed as TN. Specificity was then defined as TN/(TN+FP). The difference was calculated as CMRM value minus UMRM value, CMRM+XRM value minus UMRM+XRM value, CMRM+XRM value minus XRM value respectively.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"-3.2","spread":null},{"groupId":"OG001","value":"-3.1","spread":null},{"groupId":"OG002","value":"-5.6","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"-7.3","spread":null},{"groupId":"OG001","value":"-5.0","spread":null},{"groupId":"OG002","value":"-6.6","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"-5.4","spread":null},{"groupId":"OG001","value":"-1.6","spread":null},{"groupId":"OG002","value":"-3.1","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"-0.4","spread":null},{"groupId":"OG001","value":"-0.4","spread":null},{"groupId":"OG002","value":"-0.5","spread":null}]}]}]},{"type":"OTHER_PRE_SPECIFIED","title":"Specificity Difference in the Determination of Multifocal Malignant Breast Disease Using CMRM vs UMRM, CMRM+XRM vs UMRM+XRM, and CMRM+XRM vs XRM Verified by SoT, Breast Region Level","description":"A malignant breast was defined as FP, when the reader using the respective imaging modality assessed more breast regions as malignant as were present according to SoT. Otherwise the breast was assessed as TN. Specificity was then defined as TN/(TN+FP). The difference was calculated as CMRM value minus UMRM value, CMRM+XRM value minus UMRM+XRM value, CMRM+XRM value minus XRM value respectively.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"-4.4","spread":null},{"groupId":"OG001","value":"-5.3","spread":null},{"groupId":"OG002","value":"-7.5","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"-6.5","spread":null},{"groupId":"OG001","value":"-6.7","spread":null},{"groupId":"OG002","value":"-8.2","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"-2.3","spread":null},{"groupId":"OG001","value":"-2.0","spread":null},{"groupId":"OG002","value":"-1.9","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"1.1","spread":null},{"groupId":"OG001","value":"-0.7","spread":null},{"groupId":"OG002","value":"-0.7","spread":null}]}]}]},{"type":"OTHER_PRE_SPECIFIED","title":"Sensitivity of Detection of Multicentric Malignant Disease Verified by SoT, Breast Level","description":"For a single participant the sensitivity was defined as the proportion of malignant breast regions that were recognized by the reader using the respective imaging modality as malignant. Subsequently the point estimates were calculated based on the mean of the sensitivities across all participants. The difference was calculated as CMRM value minus UMRM value, CMRM+XRM value minus UMRM+XRM value, CMRM+XRM value minus XRM value respectively.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"47.7","spread":null},{"groupId":"OG001","value":"38.6","spread":null},{"groupId":"OG002","value":"75.0","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"56.8","spread":null},{"groupId":"OG001","value":"40.9","spread":null},{"groupId":"OG002","value":"61.4","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"47.7","spread":null},{"groupId":"OG001","value":"31.8","spread":null},{"groupId":"OG002","value":"43.2","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"34.1","spread":null},{"groupId":"OG001","value":"31.8","spread":null},{"groupId":"OG002","value":"52.3","spread":null}]}]}]},{"type":"OTHER_PRE_SPECIFIED","title":"Accuracy Difference of Presence of Bilateral Malignant Disease Verified by SoT by Clinical Investigator, Participant Level","description":"The disease state \"bilateral malignant disease\" was derived from the assessment of the different regions for each breast (right and left) for investigators for each imaging modality (UMRM, CMRM, XRM, UMRM+XRM, and CMRM+XRM) based on the following rule: If the participant had at least one breast with no malignant region , the assessment of bilateral malignant disease was categorized as \"No\". If the participant had at least one malignant lesion in both breasts, the assessment of bilateral malignant disease was categorized as \"Yes\". The proportion of correct matches of each different image set to the SoT for the existence of bilateral malignant disease were derived. The analysis was based on the difference in accuracy for the evaluation of bilateral malignant disease for the following image comparisons on a participant level. The difference was calculated as CMRM value minus UMRM value, CMRM+XRM value minus UMRM+XRM value, CMRM+XRM value minus XRM value respectively.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"0.5","spread":null},{"groupId":"OG001","value":"-0.3","spread":null},{"groupId":"OG002","value":"-0.8","spread":null}]}]}]},{"type":"OTHER_PRE_SPECIFIED","title":"Blinded Readers: Inter-reader Agreement on Sensitivity Based on Assessment for UMRM vs CMRM - Breast Region Level","description":"Inter-reader agreement was assessed by considering each breast region to have 2 possibilities (malignant disease / no malignant disease) for an assessment by the 2 image sets (UMRM and CMRM). Kappa value varies from 0 (no agreement) to 1 (perfect agreement).","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"0.47","spread":null}]}]}]},{"type":"OTHER_PRE_SPECIFIED","title":"Blinded Reader 1: Intra-reader Variability Based on Assessment for CMRM - Breast Level","description":"Intra-reader variability was assessed using a kappa on the match to SoT for the different regions within each participant (match, no match SoT). For each of the 3 readers, intra-reader agreement was assessed by considering each breast region to have 2 possibilities for an assessment by CMRM: matched SoT or did not match SoT. Kappa value varies from 0 (no agreement) to 1 (perfect agreement).","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"0.25","spread":null}]}]}]},{"type":"OTHER_PRE_SPECIFIED","title":"Blinded Reader 2: Intra-reader Variability Based on Assessment for CMRM - Breast Level","description":"Intra-reader variability was assessed using a kappa on the match to SoT for the different regions within each participant (match, no match SoT). For each of the 3 readers, intra-reader agreement was assessed by considering each breast region to have 2 possibilities for an assessment by CMRM: matched SoT or did not match SoT. Kappa value varies from 0 (no agreement) to 1 (perfect agreement).","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"0.23","spread":null}]}]}]},{"type":"OTHER_PRE_SPECIFIED","title":"Blinded Reader 3: Intra-reader Variability Based on Assessment for CMRM - Breast Level","description":"Intra-reader variability was assessed using a kappa on the match to SoT for the different regions within each participant (match, no match SoT). For each of the 3 readers, intra-reader agreement was assessed by considering each breast region to have 2 possibilities for an assessment by CMRM: matched SoT or did not match SoT. Kappa value varies from 0 (no agreement) to 1 (perfect agreement).","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"0.21","spread":null}]}]}]},{"type":"OTHER_PRE_SPECIFIED","title":"Categorical Accuracy Difference of Extent of Malignant Disease Verified by SoT by Majority Reader, Breast Region Level","description":null,"classes":[]},{"type":"OTHER_PRE_SPECIFIED","title":"Categorical Accuracy Difference of Extent of Malignant Disease Verified by Histopathology by Majority Reader, Breast Region Level","description":null,"classes":[]},{"type":"OTHER_PRE_SPECIFIED","title":"Vital Signs Change From Baseline and Follow-up 24 Hours Post Injection - Systolic and Diastolic Blood Pressure","description":"Systolic and diastolic blood pressure were measured in a supine position. Blood pressure was not to be measured on the arm used for the injection.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"-2.7","spread":"15.2"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"-2.3","spread":"9.7"}]}]}]},{"type":"OTHER_PRE_SPECIFIED","title":"Vital Signs Change From Baseline and Follow-up 24 Hours Post Injection - Heart Rate","description":"Heart rate was measured in a supine position.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"-1.7","spread":"10.1"}]}]}]},{"type":"OTHER_PRE_SPECIFIED","title":"Number of Participants With at Least One Laboratory Parameter Change From Low or Normal at Baseline to Abnormally High at Follow-up 24 Hours Post Injection","description":"Number of participants with at least one occurrence of changing from low or normal at baseline to high at follow-up.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"41","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"107","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"144","spread":null}]}]}]}],"adverseEventsModule":{"adverseEventsSummary":{"seriousAny":{"events":0,"n":439},"commonTop":["Headache"]}}}